About Cyprotex
Cyprotex is a Healthcare company based in Macclesfield (United Kingdom) founded in 1999, and was acquired by Evotec in October 2016. It operates as a predictive toxicology and in vitro and in silico ADME services provider. The company has 17 employees. Cyprotex has completed 1 acquisition, including Mabosbet. Cyprotex offers products and services including eCiphr®Cardio, eCiphr®Neuro, CellCiphr®, and 3D Microtissue Models. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Functional Services. Its legal entity is CYPROTEX US LLC.
Company details
Cyprotex PLC is a CRO that provides in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) related services. Cyprotex provides services, which include ADME screening, customised ADME assays, genomic ADME, in silico pharmacokinetics modelling and in vitro toxicology. Cyprotex has capabilities to support both phenotypic and target-based drug discovery by the development, validation and screening of cell-based assays. The company also offers Endocrine Disruption Screening Assays, physicochemical profiling and in vitro skin and ocular testing services. The company was acquired by Evotec in December 2016. The company was offering integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. Post acquisition by Evotec, they offer integrated preclinical services.
- Headquarters Macclesfield, United Kingdom
- Employees 17
- Stage Acquired
- SectorsHealthcare
- Website cyprotex.com
- Social LinkedIn X
- Acquired by Evotec (Oct 2016)
- Legal Name Cyprotex Us Llc
Products & Services of Cyprotex
Cyprotex offers a comprehensive portfolio of products and services, including eCiphr®Cardio, eCiphr®Neuro, CellCiphr®, and 3D Microtissue Models.
Monitors cardiomyocytes for drug discovery and safety testing.
Evaluates neuronal activity in preclinical drug development.
Predicts drug-induced liver injury using high content screening.
Assesses drug responses in advanced tissue models.
Funding Insights of Cyprotex
- Total Rounds 4
- First Round $2.68M
(Aug 2010)
- Investors Count 2
All 4 funding rounds of Cyprotex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | – | Grant | – | – | |
| Jan 2016 | $1.73M | Grant | – | – | |
| Sep 2013 | $12.21M | Post-IPO | – | – | |
| Aug 2010 | $2.68M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Cyprotex
Cyprotex has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Evotec, European Union and Harwood Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Harwood Private Equity is focused on UK mid-market investments. | 1999 | harwoodpe.co.uk | London, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Drug discovery and development services are provided to biopharma sector. | 1993 | evotec.com | Hamburg, Germany |
Investor details for Cyprotex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cyprotex
67 people are tracked at Cyprotex (8 in leadership, 59 in team); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
Simon Wood | Head Of Analytical Sciences | Leadership |
Mark Wenlock | Group Leader - Head Of Physical Chemistry | Leadership |
Dr. Anthony Baxter | Chief Executive Officer | Leadership |
Stephen Madden | SVP Head Global Operations Cyprotex | Leadership |
Paul Walker | Vp, Head Of Toxicology And Innovation Efficiency | Leadership |
Simon Thomas | Head Of Modelling And Simulation | Leadership |
Phil Butler | Vp, Head Of Adme, Physical Chemistry And Analytical Sciences | Leadership |
David Cerny | Vice President Of Business Development | Leadership |
John M. | Associate Scientist II | Team |
Iqra M. | Scientist I | Team |
Hayley Atkinson | Principal Scientist | Team |
Abigail Melia | Scientist | Team |
Gabriele Sakinyte | Associate Scientist | Team |
Alexander Argyle | Scientist II | Team |
Annie-May Ball | Associate Scientist II | Team |
Bharat Misra | Research Associate | Team |
Faye Cruickshank | Associate Principal Scientist | Team |
Lara Ward | Principal Scientist | Team |
James Harrison | Principal Scientist | Team |
Jennifer Meadows | Scientist | Team |
47 more people are available in the full profile.
Complete people profiles for Cyprotex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyprotex
Cyprotex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mabosbet.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
ADME, PK, and toxicity services are provided for pharmaceutical sectors. | ceetox.com | Kalamazoo, United States | 2003 | Jan 2014 | •••• |
Complete acquisition details for Cyprotex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Cyprotex
The website of Cyprotex (cyprotex.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 70.9% vs previous month
Websites whose visitors overlap most with Cyprotex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biotrondiagnostics.com | 100% | 1.5K | #9,362,675 | View details | |
| cerep.fr | 93% | – | – | View details | |
kinexpharma.com | kinexpharma.com | 91% | – | – | – |
chirhoclin.com | chirhoclin.com | 90% | – | #6,385,641 | – |
nanotherapeutics.com | nanotherapeutics.com | 90% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Cyprotex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Cyprotex (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cyprotex
Complete news archive for Cyprotex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyprotex
Cyprotex was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Cyprotex is headquartered in Macclesfield, United Kingdom. It is registered at Macclesfield, Cheshire, United Kingdom.
Cyprotex has 17 employees.
Cyprotex PLC is a CRO that provides in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) related services. Cyprotex provides services, which include ADME screening, customised ADME assays, genomic ADME, in silico pharmacokinetics modelling and in vitro toxicology. Cyprotex has capabilities to support both phenotypic and target-based drug discovery by the development, validation and screening of cell-based assays. The company also offers Endocrine Disruption Screening Assays, physicochemical profiling and in vitro skin and ocular testing services. The company was acquired by Evotec in December 2016. The company was offering integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. Post acquisition by Evotec, they offer integrated preclinical services.
Cyprotex offers eCiphr®Cardio, eCiphr®Neuro, CellCiphr®, and 3D Microtissue Models.
Cyprotex has made 1 acquisition, including Mabosbet.
Cyprotex has 3 investors. Key investors include Evotec, European Union, and Harwood Private Equity.
Cyprotex operates through Cyprotex Us Llc.
Yes. Cyprotex was acquired by Evotec in October 2016.